人类胰岛素瘤中的免疫组合化学葡萄糖类-1受体表达
Tiina Vesterinen1,2, Elina Peltola3,4, Helena Leijon1
1Department of Pathology, HUSLAB, HUS Diagnostic Center, Helsinki University Hospital, University of Helsinki, 00290 Helsinki, Finland.
International journal of molecular sciences
|October 28, 2023
概括
在胰岛素瘤中缺乏葡萄糖类-1受体 (GLP-1R) 表达,表明转移潜力和生存率较差. GLP-1R状态可以预测这些罕见的胰腺神经内分泌瘤的预后.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 病理学 病理学 病理学
背景情况:
- 胰岛素瘤是一种罕见的胰腺神经内分泌瘤,转移率为10%.
- 预测胰岛素瘤的预后是具有挑战性的,因为临床病理因素有限.
- 确定转移潜力的生物标志物对于患者管理至关重要.
研究的目的:
- 为了评估胰岛素瘤中的葡萄糖类-1受体 (GLP-1R) 表达.
- 分析GLP-1R表达与临床病理特征之间的关联.
- 为了确定GLP-1R表达与患者结果和存活率的相关性.
主要方法:
- 对52个胰岛素瘤患者的组织样本进行了回顾性分析.
- 组织学重新评估和组织微阵列构建.
- 使用单克隆抗体对GLP-1R表达进行免疫组织化学染色.
主要成果:
- 98%的非转移性胰岛素瘤表达了GLP-1R.
- 在一个非转移性瘤和所有三个转移性瘤中观察到GLP-1R表达的缺乏.
- 缺少GLP-1R与生存能力受损,瘤大小,Ki-67高,胰岛素染色较弱相关.
结论:
- 缺乏GLP-1R表达与转移性胰岛素瘤和降低整体存活率有关.
- GLP-1R表达可以作为评估转移风险的潜在生物标志物.
- GLP-1R状态可能有助于预测手术治疗胰岛素瘤患者的预后.
相关概念视频
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
Glucagon-like Receptor Agonists
334
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
334
Insulin Secretory Vesicles
5.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.0K
Insulin: Biosynthesis, Chemistry, and Preparation
393
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
393
Hypoglycemia and Glucagon
274
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
274


